ABAjay Bharadwaj

Ajay Bharadwaj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajay Bharadwaj has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Joining Two Perspectives of the Proteome with the Trypsin+HTA Protease Workflow

    by Mario M. Alba, Ajay Bharadwaj, Lindsey Becker, Ethan J. Canfield, Jonathan E. Katz, Jennifer E. Van Eyk, Simion Kreimer

    Proteolysis can be completed in a single-step, rapid (5-30 minutes) reaction using hyperthermoacidic archaeal (HTA) proteases. Protocol simplicity and stability of HTA proteases in ambient storage conditions removes many logistical barriers to widespread deployment of proteomic analysis. HTA protease cleavage selectivity is complex but quantitatively reproducible and generates peptides that negligibly overlap with trypsin. Tryptic and HTA protease peptides emphasize different proteins and provide complementary coverage of amino acid sequence and post-translational modification (PTM) sites. Digestion of a sample’s separate aliquot with HTA protease is a minor addition to trypsin-based workflows, but LC-MS analysis of both sets of peptides is not practical for large cohorts. This manuscript evaluates the identifications and reproducibility of LC-MS analysis of tryptic and HTA protease peptide mixtures. Adding HTA protease peptides to 20% increased total protein identifications by 24% on average in neat plasma and identified 216 additional biologically interesting modifications compared to conventional trypsin-only bottom-up proteomic analysis. This approach is reproducible and does not increase sample preparation or analysis time. Peptides from each protease present independent opportunities to quantify overlapping proteins and a quantification model was developed in which, for each protein, the most complete protease data is selected for primary quantitation and data from the second protease is used to infer missing values. This cross-protease inference is more accurate than minimum, mean, or nearest neighbor imputations. Finally, biomarkers discovered through HTA protease peptides are amenable to rapid HTA protease only proteomic workflows thus streamlining translation from discovery to fieldable applications.

  • Open Access

    Asporin Improves Cardiac Myocyte Response to Ischemia and Reperfusion Stress

    by Deepika Rai, Mukta Basu, Liam McCarthy, Divya Gupta, Ashley Dinh, Matthew Aryes, Ajay Bhardwaj, Pavithra Nedumaran, Reetu Thakur, Aleksandar B. Stotland, et al.

    Myocardial-Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is the accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio-protection during this phase. Asporin (ASPN), a small leucine-rich proteoglycan, modulates cardiac remodeling by limiting excessive fibrosis and protecting CMs from cell death. We investigated the therapeutic potential of ASPN using an exogenous recombinant ASPN-peptide (rASPN) and tested its effects in an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18-hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18-hours of hypoxia, followed by 12-hours of reoxygenation (simulating reperfusion), with or without rASPN. Proteomics revealed that ASPN modulates pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune-response pathways and significantly affected TGF-β signaling, a central mediator of cardiac fibrosis and remodeling post-MI. Our study demonstrates that rASPN confers protection in a human cardiac cell-based H/R model, highlighting its therapeutic potential as a biological or peptide-based intervention to mitigate R/I and adverse remodeling following MI.